Your browser doesn't support javascript.
loading
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis.
Simonds, Megan M; Freer, Samuel T; Al-Jaberi, Lina; Brescia, AnneMarie C.
Afiliação
  • Simonds MM; Nemours Biomedical Research, 1600 Rockland Rd, Wilmington, DE, 19803, USA. msimonds@nemours.org.
  • Freer ST; Nemours Biomedical Research, 1600 Rockland Rd, Wilmington, DE, 19803, USA.
  • Al-Jaberi L; Division of Rheumatology, Nemours Children's Health, 1600 Rockland Rd, Wilmington, DE, 19803, USA.
  • Brescia AC; Division of Rheumatology, Nemours Children's Health, 1600 Rockland Rd, Wilmington, DE, 19803, USA.
Rheumatol Ther ; 11(1): 143-155, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38070102
ABSTRACT

INTRODUCTION:

Fibroblast-like synoviocytes (FLS) play a critical role in inflammation that contributes to disease progression in juvenile idiopathic arthritis (JIA). In rheumatoid arthritis (RA), FLS express tumor necrosis factor alpha (TNFα). TNFα signaling has been shown to be upstream of transforming growth factor beta (TGFß) signaling. Overexpression of TNFα and TGFß, as well as related proteins, can cause increased inflammation in RA. In this study, we examine the effects of inhibiting TNFα signaling with adalimumab on FLS isolated from synovial fluid of patients with JIA.

METHODS:

Synovial fluid samples were selected from 41 patients in our repository. Of these samples, 23 were diagnosed with persistent oligoarticular JIA and 18 were diagnosed with extended oligoarticular JIA. All samples were taken prior to patients extending to a polyarticular course, or what we termed extended-to-be (ETB), and were on no medications or nonsteroidal anti-inflammatory drugs (NSAIDs) only at the time of arthrocentesis. For cell studies, FLS were isolated from synovial fluid and treated with adalimumab for 24 h. Protein antibody arrays were performed by RayBiotech, Inc. according to their protocols.

RESULTS:

In persistent FLS, TNFα (fold change [FC] = 1.2 p = 0.001), TGFß (FC = 1.5 p = 0.001), lymphotoxin alpha (LTα) (FC = 4.3 p = 0.015), soluble tumor necrosis factor receptor 1 (sTNFRI) (FC = 5.1 p = 0.008), and soluble tumor necrosis factor receptor 2 (sTNFRII) (FC = 3.8 p = 0.025) were significantly elevated in adalimumab treated cells compared to untreated cells. In ETB FLS, TNFα was significantly elevated (FC = 1.04 p = 0.023) while TGFß (FC = 1.03 p = 0.037) was significantly decreased in adalimumab-treated cells compared to untreated cells.

CONCLUSIONS:

This data suggests that, after only 24 h, adalimumab is effective at decreasing inflammation that occurs downstream of initial TNFα signaling in extended-to-be fibroblast-like synoviocytes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article